Why Psychedelics Reach What Antidepressants Miss
What Psychedelics Actually Do to a Depressed Brain
Part two of two. On Tuesday I wrote about the scale of the depression epidemic and the limits of current treatment. Today I want to go into the brain — what psychedelics do there, why it is different from anything we have had before, and what that means for the people who haven't been helped by anything else.
The network that won't stop talking
There is a network of brain regions that becomes most active when you are not focused on anything in particular. When you are resting, waiting, staring out a window.
Neuroscientists call it the Default Mode Network — the DMN.
What the DMN does, in plain terms, is generate the narrative of who you are. It is responsible for self-referential thinking — replaying the past, anticipating the future, constructing and maintaining the story of the self. When it is working well, this is useful. When it is dysregulated, it becomes the machinery of rumination.
In depression, the DMN tends to be overactive and rigid. The medial prefrontal cortex — one of its central hubs — shows excessive activity, and research has found an inverse correlation between this overactivity and depressive symptoms: the more active, the worse the depression.
The network gets stuck in grooves. The same stories, the same weight, the same loops playing over and over: “"What is wrong with me?” “Nothing will change.” “This is just who I am.”
A systematic review covering 28 human neuroimaging studies, found that in depression, higher within-DMN connectivity and lower connectivity between the DMN and other networks correlated directly with baseline depression severity.
In plain terms: the more the DMN was talking only to itself — looping internally without connecting to the rest of the brain — the worse the person's depression. The network had become self-contained and self-reinforcing. The rumination feeds the isolation, and the isolation feeds the rumination. The brain gets better and better at doing the one thing that is making everything worse.
What psychedelics do to this system
Across every study that has looked at this — and a mega-analysis published in Nature Medicine in April 2026 brought together 11 independent datasets, 267 participants, and over 500 brain scans to find out — psychedelics do something consistent and striking to large-scale brain organisation.
Psychedelics increase communication between networks that do not normally talk to each other.
To understand why that matters, it helps to know that the brain operates in a rough hierarchy.
At the top are the high-level association networks — including the DMN — which handle abstract thinking, self-reflection, planning, meaning-making.
At the bottom are the more basic sensory and motor networks, which handle what is happening right now in the body and the immediate environment: what you see, what you hear, what you feel physically.
In a healthy brain these levels communicate, but they stay mostly in their lanes. In depression, the top level — the self-referential machinery — becomes dominant and increasingly disconnected from present-moment experience.
The body is here. The mind is somewhere else entirely, running its loops.
Psychedelics flatten this hierarchy temporarily. The high-level networks and the sensory networks start exchanging information more freely. Abstract thought and present-moment bodily experience become less separate.
This is part of why people in sessions often describe a quality of radical presence — the brain is, for a period, less able to maintain the usual separation between thinking about experience and actually having it.
At the same time, within-network connectivity — the tight, self-reinforcing loops inside individual networks like the DMN — decreases. Not dramatically, and the mega-analysis was careful to note that earlier studies had overstated this effect. But the directionality is consistent: the brain becomes less modular, less siloed, more globally integrated.
Think of it this way. The depressed brain is like a city where certain neighbourhoods have become completely self-contained — the roads between them and the rest of the city are barely used. Traffic only circulates internally. The same routes, the same destinations, over and over. Psychedelics open new roads. Not permanently, but long enough for the system to reorganise.
This finding held across psilocybin, LSD, DMT, mescaline, and ayahuasca — five different compounds, three continents, multiple independent research groups. The core signature was the same.
The depressed brain is like a city where certain neighbourhoods have become completely self-contained — the roads between them and the rest of the city are barely used. Traffic only circulates internally. The same routes, the same destinations, over and over. Psychedelics open new roads. Not permanently, but long enough for the system to reorganise.
When the brain loosens, symptoms follow
The review found something important about what happens when the DMN is disrupted this way in people with depression. A study that was included in the review found that psilocybin therapy reduced depressive symptoms for up to six weeks post-treatment, and that this effect was linked to one specific brain change: reduced modularity of the DMN, and increased integration between it and other networks.
What this means is that the brain becoming less stuck was directly correlated with people feeling better.
And, even more important to note: this more flexible, integrated brain state did not just appear during the session but it persisted in the recovered state of patients who responded to treatment. The system had reorganised, not just temporarily shifted.
And critically — this effect was not seen with SSRIs. In the same study, escitalopram did not produce the same reduction in brain modularity.
The two treatments produced similar symptom reduction at least based on some measures, but through apparently different mechanisms.
One - the antidepressant, was flattening the emotional signal.
The other one, the psilocybin, was changing how the brain was organised.
Emotions stay intact — and that matters more than it sounds
This brings me to what I think is one of the most clinically significant findings in recent psychedelic research.
A study published in 2025, compared directly what psilocybin and escitalopram do to emotional processing in the brain.
The antidepressant significantly reduced the brain's responsiveness to emotional stimuli — across the board, not selectively.
Psilocybin did not. Emotional reactivity remained intact.
This is not a small distinction. What it means, practically, is that in a psilocybin session, the emotional material that has been frozen or avoided or numbed — the grief, the fear, the things that have been circling for years in the DMN without resolution — becomes accessible rather than further dampened.
The psychedelic journey does not bypass the emotional content. It creates conditions in which the brain can actually engage with it differently.
Why the effects last - enter neuroplasticity
One of the things that makes psychedelics genuinely unusual as a treatment is the duration of effect relative to the number of sessions. All it is needed is one or two administrations, with effects sustained at follow-up for six to twelve months in multiple trials. That is not how most pharmacological interventions work.
Part of the explanation likely lies in what the brain does after the session. Psychedelics appear to temporarily increase the brain's capacity to form new connections and reorganise existing ones — what neuroscientists call neuroplasticity. Think of it as the brain becoming briefly more malleable, more open to change, than it normally is in adult life. That window of increased malleability is probably part of why a single session can produce changes that persist for months.
This is why preparation and integration are not optional add-ons to psychedelic therapy. They are the work.
The session creates a window of neurological flexibility and plasticity. What happens before, during and after that window — what is brought to it, how it is held, what is done with it afterwards — determines what the reorganisation actually looks like.
What this means in practice
What strikes me most about this research — as a social scientist and as someone who has worked with this medicine and experienced what it does — is that the science is describing something that practitioners have been observing for years.
The sense that the experience creates access to things that were previously locked.
That it allows people to be with their own emotional material in a way that feels different from anything else they have tried.
That the changes, when they come, feel less like symptom relief and more like something structural has shifted.
The neuroscience is now giving us language for why that might be true. Psychedelics are not magic. But they appear to do something specific and measurable to the way the brain organises itself — something that creates a genuine window for change, if what happens in that window is held well.
This is exactly what shapes the design of our work at Hearts Door Retreats. The preparation support before a retreat is not a formality — it is how we help people identify what they are bringing into that window, so that the neurological opening the medicine creates has something real and intentional to work with.
And the integration support afterwards is where the reorganisation gets anchored — where what shifted in the brain becomes something that actually changes how a person lives.
Without that container, the window opens and closes without being fully used.
And during the retreat itself, the breathwork and body-oriented practices are not there to fill time between the ceremony and the meals. They are there because the research points to something the body already knows: that coming back into present-moment sensory experience — out of the loops of the self-referential mind and into what is actually happening right now, physically, in the body — is itself part of the healing.
We are not working around the nervous system. We are working with it, deliberately, at every stage of the process.
Ioana is a social scientist, psychedelic facilitator, and co-founder of Hearts Door Retreats. She has published research on microdosing and wellbeing at Tilburg University, The Netherlands.
At The Heart's Door, we work with psilocybin in ceremonial contexts and support structured integration practices. Curious about our retreats combining psilocybin, breathwork and body-oriented practices? Read about our work here
